EBNA-1 anticorps (AA 551-641) (HRP)

N° du produit ABIN1415469

Cet anticorps anti-EBNA-1 Polyclonal Lapin conjugué à HRP (ABIN1415469) détecte spécifiquement EBNA-1 dans WB, ELISA, IHC (p) et IHC (fro). L’anticorps est réactif avec des échantillons de Epstein-Barr Virus (EBV) et Virus.

Aperçu rapide pour EBNA-1 anticorps (AA 551-641) (HRP) (ABIN1415469)

Antigène: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Reactivité: Epstein-Barr Virus (EBV), Virus

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EBNA-1 est conjugé à/à la HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-EBNA-1 anticorps (HRP)

Épitope: AA 551-641

Réactivité croisée: Virus

Réactivité croisée (Details): Epstein Barr Virus

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from EBV Nuclear Antigen

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur EBNA-1

Antigène: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Autre désignation: EBV Nuclear Antigen

Classe de substances: Viral Protein

Sujet:

Synonyms: EBNA1, EBNA-1, EBV nuclear antigen 1, Epstein Barr nuclear antigen 1, Epstein Barr virus, BKRF1, Epstein-Barr nuclear antigen 1, EBV nuclear antigen 1,

Background: Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.